Is Riboxiclib/Calilon a chemotherapy drug or a targeted drug?

Ribociclib is not a chemotherapy drug in the traditional sense, but a targeted therapy drug, specifically a cell cycle-dependent kinase 4/6 (CDK4/6) inhibitor. This type of drug intervenes in the abnormal proliferation of tumor cells by precisely inhibiting key proteins related to the cell cycle, thereby achieving the purpose of controlling tumor progression. Different from chemotherapy drugs, chemotherapy usually kills or inhibits rapidly dividing cells, which often has a greater impact on normal cells, leading to obvious side effects such as hair loss, bone marrow suppression, and gastrointestinal reactions. Riboxiclib, as a targeted drug, mainly targets specific signaling pathways of tumor cells. It has a different side effect spectrum and is relatively better tolerated.

The mechanism of action of Riboxiclib is to inhibitCDK4/6 enzyme activity. The growth of breast cancer, especially hormone receptor-positive (HR+), HER2-negative tumor cells, depends on the cyclin D1-CDK4/6-Rb pathway. By blocking this pathway, Riboxil causes the cell cycle to arrest in the G1 phase, preventing tumor cells from continuing to divide and proliferate. This precise blocking mechanism is a typical feature of targeted drugs and is also the fundamental difference between them and chemotherapy.

Of note, reboxiclib is often given in combination with endocrine therapies, such as aromatase inhibitors or fulvestrant. The purpose is to improve the therapeutic effect and prolong the disease progression time by dually inhibiting tumor growth signals. This combination strategy has been clearly recommended in international and domestic breast cancer treatment guidelines, and has gradually become an important model for the first-line treatment of HR+/HER2- advanced breast cancer.

From an application perspective, the launch of Riboxil represents the trend of breast cancer treatment gradually transforming from traditional chemotherapy to precision targeted therapy. This drug not only improves the patient's quality of life, but also reduces the systemic toxic side effects caused by chemotherapy.

Reference materials:https://us.kisqali.com/